Cardiology

Empagliflozin, a sodium-glucose cotransporter-2 inhibitor, induces a rapid and sustained reduction in serum uric acid levels and decreases the risk of cardiovascular death or hospitalization for heart failure.

Health Canada approves use in patients with common form of heart disease.

Test your knowledge of Canada’s harmonized prevention and treatment guideline.

But a garlic dietary supplement slightly increased LDL.

SOGC menopause and cardiovascular disease guideline details benefits, risks.

In rheumatoid arthritis patients with a history of cardiovascular disease, the risk of major adverse cardiovascular events is higher with tofacitinib than with tumor necrosis factor inhibitors.

The guideline is an update to a 2018 iteration and adds 48 fresh recommendations.

Having previously updated the risks specified on the product monograph for one type of Janus Kinase inhibitor, Health Canada now says it can't rule out similar risks for other types.